![]() |
Market Research Report
Acute Myeloid Leukemia - Epidemiology Forecast to 2029 |
||||||
Published by | GlobalData | Product code | 943319 | ||||
Published | Content info | 37 Pages Delivery time: 1-2 business days |
|||||
Price |
|
Acute Myeloid Leukemia - Epidemiology Forecast to 2029 | ||
Published: June 29, 2020 | Content info: 37 Pages |
|
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow in which the bone marrow produces abnormal red blood cells, white blood cells, or platelets, and generally progresses at a rapid pace. AML is more common in the elderly, is associated with severe complications and high mortality, and accounts for a disproportionately high number of cancer-related deaths. AML is often called acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia.
In 2019, there were 72,164 diagnosed incident cases of AML in the 8MM in men and women combined for ages 18 years and older. GlobalData epidemiologists estimate that globally, cases will rise to 90,264 at an Annual Growth Rate (AGR) of 2.51% by 2029. Urban China is expected to contribute the highest proportion of growth over this forecast period with diagnosed incident cases growing from 29,535 in 2019 to 39,991 in 2029 at an AGR of 3.54%. Similarly, the five-year diagnosed prevalent cases of AML in the 8MM are expected to grow from 99,624 cases to 124,065 cases by 2029.
The AML Epidemiology series will allow you to -